This is consistent with the increased mutations in WT1 (22.9% of cases), which is frequently mutated in AML and associated with poor prognosis.33 Notably, we did not find enrichment of genes and pathways previously implicated in high-risk disease such as PTEN, RAS, PRC2, and TP53. This evidence concerns the gene TP53 and acute myeloid leukemia.